How To Reduce Batch-to-Batch Variation In Cell Therapy Manufacturing

As the patient’s immune cells are the starting materials, inherent biological variability leads to CAR-T manufacturing. Additional critical raw materials such as plasmids, viral vectors, lipid nanoparticles, etc. also have batch-to-batch variability, which means the entire production process is a constant balancing act of adjusting the manufacturing process to create a standardized manufacturing. Cell & Gene Chief Editor Erin Harris welcomed Donna Rill, Chief Technology Officer at Triumvira Immunologics and Omkar Kawalekar, Ph.D., Senior Manager, Deloitte Consulting for a discussion on practical ways to overcome the challenges associated with batch-to-batch variation. 

Available on-demand thanks to the support of Entegris.

Don't have time to watch the full video? Check out these segments by topic:

• Defining The Root Cause Of Batch-To-Batch Variability
• The Biggest Challenges In Autologous Cell Therapy Manufacturing
• Operations Steps For Reducing Batch-To-Batch Variability
• Understanding Critical Quality Attributes (CQA) Impact On Variability
• The Biggest Challenges In Allogeneic Cell Therapy Manufacturing
• Analytical Challenges Facing Autologous Cell Therapies
• Reducing Variability For Apheresis Material For Autologous Cell Therapy
• Improving Data Collection And Tracking To Reduce Batch-to-Batch Variability
• Best Practices For Reducing Variability Without Increasing Regulatory Burden
• How Automation Reduces Batch-To-Batch Variability
• Audience Q&A